Both Mounjaro (tirzepatide) and Ozempic (semaglutide) are GLP-1–based medications that help reduce appetite—but tirzepatide may offer greater weight-loss benefits because it targets both GLP‑1 and GIP receptors.
In the SURPASS‑2 clinical trial involving adults with type 2 diabetes, those taking tirzepatide experienced significantly more weight loss compared to those on semaglutide 1 mg:
- At 6 months, tirzepatide users lost 4.3% more body weight than semaglutide users (mean difference −4.3%, 95% CI −4.7 to −4.0) View the study on JAMA Network
- After 12 months, the difference grew to −6.9% (95% CI −7.9 to −5.8), demonstrating superior long-term efficacy Read the clinical data on PubMed
Another study, SURMOUNT‑5, compared tirzepatide to semaglutide in adults with obesity and no diabetes. It found:
- 20.2% average weight loss with tirzepatide vs. 13.7% with semaglutide over 72 weeks.
- Nearly a third (32%) of tirzepatide users lost at least 25% of their body weight, compared to just 16% on semaglutide read more
These head-to-head studies strongly suggest that tirzepatide offers a greater reduction in body weight than semaglutide (Ozempic/Wegovy) while maintaining a similar safety profile.
| Feature | Mounjaro (Tirzepatide) | Ozempic (Semaglutide) |
|---|---|---|
| Drug Type | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Approved For | Type 2 diabetes, Obesity | Type 2 diabetes, Obesity |
| Average Weight Loss (SURMOUNT-5) | 20.2% over 72 weeks | 13.7% over 72 weeks |
| Users Losing ≥25% Body Weight | 32% | 16% |
| Mechanism of Action | Targets both GIP & GLP-1 receptors to reduce appetite and improve insulin sensitivity | Targets GLP-1 receptors to slow digestion and reduce appetite |
| Clinical Trial Highlights | SURPASS-2, SURMOUNT-5 | STEP trials, SURPASS-2 (comparison arm) |
| Weight Loss vs Ozempic (6 mo) | −4.3% more body weight lost | — |
| Weight Loss vs Ozempic (12 mo) | −6.9% more body weight lost | — |
| External Sources | JAMA Network PubMed, Reuters | |
Conclusion: Which One Is Right for You?
While both Mounjaro and Ozempic are powerful tools in the fight against obesity and type 2 diabetes, clinical research suggests that Mounjaro (tirzepatide) may offer greater weight-loss potential and metabolic improvements due to its dual action on GLP‑1 and GIP receptors. That said, the right medication for you depends on individual health factors, goals, and what your doctor recommends.
If you’re considering one of these medications, talk to a healthcare professional. These are not quick fixes, but science backed therapies that when combined with lifestyle changes can make a real difference.
Suggested Reads
Starting Mounjaro: Why I Decided to Try 2.5mg and What I Hoped to Achieve
A personal journey into week one of using Mounjaro, appetite changes, and mindset shifts post-pregnancy.
The Anti-Inflammatory Diet Basics
Learn how simple diet changes can support reduced inflammation, better mood, and long-term metabolic health.
The Role of Sleep in Immune System Support
Discover why getting quality rest is key to healing, hormone balance, and weight management.
Disclaimer:
This article discusses GLP-1 medications such as Mounjaro (tirzepatide) and Ozempic (semaglutide) for informational purposes only. It is not intended to diagnose, treat, or recommend any specific medical course of action. These medications can have side effects and are not suitable for everyone. Always speak with a licensed healthcare provider before starting or changing any treatment plan, especially when it involves prescription medications.
Ava Sinclair
Ava Sinclairis a wellness expert and writer with a passion for integrative health, sustainable living, and everyday rituals that support long-term well-being. She brings a thoughtful, science-informed perspective to topics that connect body, mind, and lifestyle.
